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We have explored the potential of proteomic proﬁling to contribute to the delineation of the range of expression and subcellular
localization of aldehyde dehydrogenases (ALDHs) in lung adenocarcinoma. In-depth quantitative proteomics was applied to 40
lungadenocarcinomacelllinesresultingintheidentiﬁcationoftheknownmembersoftheALDHfamily.Substantialheterogeneity
inthelevelandoccurrenceofALDHsintotallysatesandonthecellsurfaceandintheirreleaseintotheculturemediawasobserved
based on mass spectrometry counts. A distinct pattern of expression of ALDHs was observed in cells exhibiting epithelial features
relative to cells exhibiting mesenchymal features. Strikingly elevated levels of ALDH1A1 were observed in two cell lines. We also
report on the occurrence of an immune response to ALDH1A1 in lung cancer.
1.Introduction
Aldehyde dehydrogenases (ALDHs) constitute a large family
of enzymes that catalyze the oxidation of endogenous and
exogenousaldehydestocarboxylicacids.Thediﬀerentfamily
members exhibit heterogeneous tissue distribution and have
been localized predominantly in the cytosol and mitochon-
dria. ALDHs have been investigated primarily based on their
gene expression, their immunohistochemical localization
and based on their activity. Cell sorting techniques have been
utilized to enrich for cells expressing these enzymes based
on activity. The relevance of ALDHs to cancer stems in part
from the role they may play during carcinogenesis, their
association with therapeutic resistance, and more recently
from a distinct pattern of expression of ALDH1A1 and
ALDH3A1 in cancer stem cells, which has been exploited
as a means to deﬁne this cell population in tumors [1–3].
Several studies have pointed to evidence for epithelial to
mesenchymal transitions in cancer stem cells, deﬁned, in
part, based on their ALDH expression or activity [4, 5].
WhileALDH1and3dominatethecancerstemcellliterature,
other ALDHs have also been explored. High-level expression
of ALDH1B1 was observed in colon cancer by immunohis-
tochemistry [6]. Moderate to strong staining for ALDH4A1,
ALDH5A1, and ALDH6A1 was observed in most cancer
tissue in Protein Atlas (http://www.proteinatlas.org/). Strong
expression of ALDH7A1 has been found in human prostate
cancer cell lines, primary tumors, and matched bone metas-
tases, with evidence of its functional involvement in the for-
mation of bone metastases [7]. Comparative analysis of hep-
atocellular carcinoma tissue and adjacent nontumor tissue
identiﬁed changes in ALDHs1-3 proteins in tumor tissue [8].
Several studies have explored the biological signiﬁcance
of ALDHs speciﬁcally in lung cancer and have provided sup-
portive evidence for the association between ALDH activity
and lung cancer stem cells [9]. Flow cytometric analysis
of a panel of lung cancer cell lines and patient-derived2 International Journal of Proteomics
tumors revealed the occurrence of a subpopulation of cells
with elevated ALDH activity in most non-small cell lung
cancers, which correlated with ALDH1A1 expression [10].
Immunohistochemical staining of a large panel of primary
tumors revealed a signiﬁcant correlation between ALDH1A1
expression and poor prognosis in patients, including those
with early stage disease [10]. Likewise, in another study,
expression of ALDH1 was found to be positively correlated
with the stage and grade of lung tumors and related to
a poor prognosis for patients with early-stage lung cancer
[11]. Expression analysis of sorted cells revealed elevated
Notch pathway transcript expression in ALDH-positive cells.
Suppression of the Notch pathway resulted in a signiﬁcant
decreaseinALDH-positivelungcancercellswithconcordant
reduction in tumor cell proliferation and clonogenicity [10].
Downregulation of ALDH isozymes aﬀects cell growth, cell
motility, and gene expression in lung cancer cells [12]. Other
ALDHs have also been explored in lung cancer. ALDH3B1
is expressed in a tissue-speciﬁc manner and in a limited
number of cell types. ALDH3B1 expression was found to
be upregulated in a high percentage of human tumors,
particularly lung tumors [13].
In general, most studies of ALDHs in lung cancer have
focused on particular members of the family. In-depth
proteomic proﬁling allows delineation of proteins expressed
in tumor cells and in subcellular compartments. In this
study we applied quantitative in-depth proteomic proﬁling
to assess the occurrence of ALDHs in whole lysates of
40 lung adenocarcinoma cell lines and to examine their
associationwiththecellsurfaceandtheextentoftheirrelease
into culture media. ALDH1A1 was further explored as a
tumorantigenthatinducesanautoantibodyresponseinlung
cancer.
2. Methods
2.1. Lung Adenocarcinoma Cell Line Culture. Cells were
grown in DMEM media (Invitrogen) containing 0.1% of
dialyzed fetal bovine serum (FBS) (Invitrogen) and 13C-
lysineinsteadofregularlysine,for7passages(1:2)according
to the standard SILAC protocol [14]. Incorporation of 13C
Lys isotope exceeded 90% of the total protein lysine content.
The same batch of cells was used for extracting cell surface
proteins and for analysis of conditioned media and whole-
cell lysate proteins. The secreted proteins were obtained
directly from the cell conditioned media after 48h of culture.
Cells and debris were removed by centrifugation at 5000×g
and ﬁltration through a 0.22μM ﬁlter. Total extracts of cells
were obtained by sonication of ∼2×107 cells in 1mL of PBS
containing the detergent octyl glucoside (OG) (1% w/v) and
protease inhibitors (complete protease inhibitor cocktail,
Roche Diagnostics, Germany) followed by centrifugation at
20,000×g.
2.2. Capture of Cell Surface Proteins. T oi s o l a t ec e l ls u r f a c e
proteins, ∼2 × 108 cells were biotinylated in the culture
plate after extensive PBS rinsing, with 10mL of 0.25mg/mL
of Sulfo-NHS-SS-BIOTIN in PBS at room temperature
(23-24◦C) for 10min. The residual biotinylation reagent
was quenched with 10mM lysine. Protein extraction was
performedinasolutioncontainingNP40detergent2%(v/v)
with cell disruption by sonication followed by centrifugation
at 20,000×g. Biotinylated proteins were chromatograph-
ically isolated by aﬃnity chromatography using 1mL of
UltraLink Immobilized NeutrAvidin (Pierce) according to
manufacturers’ instruction. Proteins bound to the column
were recovered by reduction of the biotinylation reagent with
5mL of a solution containing 65μMol of DTT and 1% octyl
glucoside (OG) detergent for 1h at 37◦C. Eluted proteins
were subsequently alkylated with 200μMol of iodoacetamide
at room temperature.
2.3. Fractionation of Cell Extracts. Cell surface, conditioned
media, and total extract were fractionated by reversed-
phase chromatography, using, respectively 500μg, 1mg, and
1mg of total protein. All the cell extracts were reduced
and alkylated with iodoacetamide prior to chromatography.
Separation was performed in a POROS R1/10 column
(Applied Biosystems—4.6 × 50mm) at 2.7mL/min using
a linear gradient of 10 to 80% of organic solvent over
30-minute run. Solvent system used was aqueous solvent,
5% acetonitrile/95% water/0.1% of triﬂuoroacetic acid;
organic solvent, 75% acetonitrile/15% isopropanol/10%
water/0.095%triﬂuoroaceticacid.Fractionswerecollectedat
a rate of 3 fractions/minute.
2.4. Protein Identiﬁcation by LC-MS/MS. Protein digestion
andidentiﬁcationbyLC-MS/MSwasperformedasdescribed
previously [15]. Brieﬂy, each one of the reversed-phase
fractionswasindividuallydigestedin-solutiondigestionwith
trypsin (400ng/fraction) and grouped into 24 to 27 pools
for each cell line and each compartment (i.e., cell surface,
conditioned media, and soluble whole-cell lysate) based
on chromatographic features. Pools were individually ana-
lyzed by LC-MS/MS in a LTQ-Orbitrap mass spectrometer
(Thermo-Finnigan) coupled to a nanoﬂow chromatography
system (Eksigent) using a 25cm column (PicoFrit 75μMI D ,
New Objectives, packed in-house with Magic C18 resin) over
a90-minutelineargradient.Acquireddatawasautomatically
processed by the Computational Proteomics Analysis System
(CPAS)[16].Thetandemmassspectraweresearchedagainst
version 3.57 of the human IPI database. A variable modiﬁca-
tion of 6.020129 mass units was added to lysine residues for
database searching to account for incorporation of the heavy
lysine isotope. We applied the tools PeptideProphet [17]a n d
ProteinProphet [18] to estimate the signiﬁcance of peptide
and protein matches. Identiﬁcations with a PeptideProphet
probability of greater than 0.2 were selected and submitted
to ProteinProphet. The latter infers a minimal set of proteins
that explain the peptide evidence, assigning a probability to
each protein based on the combined peptide probabilities.
The derived protein identiﬁcations were ﬁltered at a <5%
error rate based on the probability that the best match
obtained would fall in the distribution of random database
matches [19]. A spectral counting method [20]w a su s e dt o
estimate protein enrichment for each compartment.International Journal of Proteomics 3
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Figure 1: Extent of peptide coverage of ALDH1A1 in cell line H522 in the TCE, media, and cell surface, across the ALDH1A1 protein
sequence. Blue bar: dbSNP; red bar: N-acetylserine; black bar: conﬂict, V->I at 162; tan bar: non-Cys-containing tryptic peptide; orange
bar: Cys-containing tryptic peptide; light tan bar: N-linked non-Cys-containing tryptic peptide; light orange bar: N-linked Cys-containing
peptide.
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Figure2:DiﬀerentialexpressionofALDH1A3,ALDH1B1,andALDH18A1betweencelllineswithepithelialandcelllineswithmesenchymal
features based on MS/MS counts. A Mann-Whitney test was performed using MS/MS counts of epithelial and mesenchymal cell lines.
ALDH1A3 and ALDH1B1 have signiﬁcantly higher expression from TCE in epithelial cells as compared to mesenchymal ones, with a P value
of 0.007 and 0.030, respectively. ALDH18A1 has signiﬁcant higher expression from the cell surface in epithelial as compared to mesenchymal
with a P value of 0.042.
2.5. Two-Dimensional Polyacrylamide Gel Electrophoresis (2D
PAGE). Proteins derived from the extracts of the cultured
H522 lung adenocarcinoma cell line were separated into two
dimensions as described previously [21]. Brieﬂy, cultured
NCI-H522 cells were lysed in solubilization buﬀer (8M
urea (Bio-Rad), 2% Nonidet P-40, 2% carrier ampholytes,
pH 4–8 (Gallard/Schlesinger, Carle Place, NY), 2% ß-
mercaptoethanol, and 10mM PMSF). 200μgo fs o l u b i -
lized proteins were applied onto isoelectric focusing gels.
Isoelectric focusing was performed using pH 4–8 carrier
ampholytes at 700V for 16h, followed by 1000V for an
additional 2h. The ﬁrst-dimension gel was loaded onto the
second-dimension gel, after equilibration in 125mM Tris
(pH 6.8), 10% glycerol,2% SDS, 1% DTT, and bromophenol
blue. For the second-dimension separation, a gradient of
11–14% acrylamide (Crescent Chemical, Hauppauge, NY)
was used. The resolved proteins were transferred to an
Immobilon-P polyvinylidene diﬂuoride (PVDF) membrane
(Millipore, Bedford, Mass). Protein patterns in some gels
were visualized directly by silver staining or Sypro Ruby
staining.
2.6. Western Blotting and Image Analysis. After transfer,
membranes were incubated with a blocking buﬀer consisting
of PBS and 0.1% Tween-20 containing 1.8% nonfat dry milk
for 2h. The membranes were incubated for 1h at room tem-
perature with serum obtained from either patients or control
individuals as a source of primary antibody at a 1:100
dilution. Some additional membranes were incubated with
anantibodytoALDH1A1tovisualizetheprotein.Afterthree
washeswithwashingbuﬀer(PBScontaining0.1%Tween20),
themembraneswereincubatedwithhorseradishperoxidase-
conjugated sheep anti-human IgG (Amersham Biosciences,
Piscataway, NJ) at a dilution of 1:1000 for 1h at room
temp. Immunodetection was accomplished by enhanced
chemiluminescence (Amersham Biosciences) followed by
exposure on Hyperﬁlm MP (Amersham Biosciences). Films
were digitized with a Kodak CCD camera. The spots on each
i m a g ew e r ed e t e c t e da n dq u a n t i ﬁ e da sp r e v i o u s l yd e s c r i b e d
[21]. After immunoblotting, all membranes were Coomassie
Blue stained, and the patterns obtained were compared to
those of the ﬁlms in order to determine the locations of
reactive spots. Spot integrated intensities were normalized4 International Journal of Proteomics
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Figure 3: Extent of peptide coverage of ALDH1A3 across cell lines based on spectral counts from MS data.
by dividing by the intensity of a reference HSP27 protein
spot. HRP-conjugated goat anti-mouse secondary antibody
was spiked into the sheep anti-human cocktail at a 1:1000
dilution to facilitate detection.
2.7. Statistical Analysis. The data was analyzed using one-
sided Rank-Sum tests.
3. Results
3.1. Occurrence of ALDHs among Lung Adenocarcinoma Cell
Lines and in Subcompartments. Comprehensive proteomic
proﬁling of 40 lung cancer cell lines resulted in the identi-
ﬁcation of known members of the ALDHs family in one or
more cell lines. There was substantial heterogeneity in the
abundance of individual family members among cell lines
and in their occurrence and distribution between whole-
cell lysates, on the cell surface and their release into the
media of cultured cells (Table 1). ALDH1A1, ALDH1A3,
ALDH2, ALDH3A1, ALDH7A1, and ALDH9A1 had more
than 1,000 total MS counts each in total cell extracts across
cell lines. ALDH1A1 and ALDH3A1 exhibited discordant
expression with an overall total of MS counts for ALDH1A1
exceeding that of ALDH3A1 (Table 1), with some cell lines
yielding high MS counts for ALDH1A1 with low counts or
undetectable for ALDH3A1. The highest MS counts were
observed for ALDH2 and ALDH1A1. However, whereas
ALDH2 was relatively uniformly distributed across cell lines,
expression of ALDH1A1 was more limited to just a few cell
lines. Notably, cell line H522 yielded extremely high MS
counts for ALDH1A1 relative to most other cell lines, and
relative to other ALDHs (Table 2). Several ALDH proteins
for which we provide evidence of expression in lung cancer
cell lines (Table 1) were previously not characterized in lung
cancer. ALDH9A1 was identiﬁed in most cell lines and was
among the most abundant ALDH proteins identiﬁed based
on spectral counts.
3.2. Occurrence of ALDHs in the Extracellular Compartment.
We sought to determine the occurrence of ALDHs on the
cell surface and their release into culture media. Whereas
all ALDH proteins were identiﬁed in total cell extracts
(TCE), for most proteins a signiﬁcant fraction was observed
in both the cell surface fraction (Surf) and the media
(Med) (Table 1). For example, ALDH1A1 in H522 was
predominant in both the TCE and Med (Table 2)w h e r e a s
other proteins (e.g., ALDH3A2 and ALDH5A1) displayed a
substantial proportion of protein abundance on the cell sur-
face (Table 1). We examined whether MS data was suggestive
oftheoccurrenceofcleavageformsofALDHsinthemediaor
on the cell surface. However, the data obtained pertaining to
peptide representation of the proteins was not suggestive of
cleavage, or alternatively spliced forms of proteins associated
with the cell surface or, for that matter, with their release into
the media as exempliﬁed for ALDH1A1 in H522 (Figure 1).
3.3. Diﬀerential Expression of ALDHs Based on Epithe-
lial/Mesenchymal Features. Twenty-ﬁve of the 40 cell linesInternational Journal of Proteomics 5
Table 1: Identiﬁed Aldehyde Dehydrogenases in the total cell extracts (TCE), Media (Med) and the cell surface (Surf) across 40 lung
adenocarcinoma cell lines based on mass spectrometry (MS/MS counts for corresponding peptides).
Gene symbol Protein description
MS/MS
counts
(TCE)
MS/MS
counts
(Med)
MS/MS
counts
(Surf)
Unique
peptides Chromosome Length MW
ALDH16A1 Aldehyde dehydrogenase family 16
member A1 31 79 81 19 19 802 85127
ALDH18A1 Delta-1-pyrroline-5- carboxylate
synthase 354 5 344 20 10 795 87302
ALDH1A1 Retinal dehydrogenase 1 4961 2640 1463 37 9 500 54731
ALDH1A2 Retinal dehydrogenase 2 10 1 1 5 15 480 53060
ALDH1A3 Aldehyde dehydrogenase family 1
member A3 1267 256 299 31 15 512 56108
ALDH1B1 Aldehyde dehydrogenase X,
mitochondrial 843 22 384 29 9 517 57217
ALDH1L1 Aldehyde dehydrogenase family 1
member L1 5 3 3 8 3 505 55394
ALDH1L2 Aldehyde dehydrogenase family 1
member L2, mitochondrial 11 0 51 15 12 923 101776
ALDH2 Aldehyde dehydrogenase,
mitochondrial 4964 889 1665 32 12 517 56381
ALDH3A1 Aldehyde dehydrogenase, dimeric
NADP-preferring 1149 44 116 27 17 453 50379
ALDH3A2 Fatty aldehyde dehydrogenase 772 44 457 23 17 485 54848
ALDH3B1 Aldehyde dehydrogenase family 3
member B1 3 0 20 6 11 468 51840
ALDH3B2 Aldehyde dehydrogenase family 3
member B2 3 0 0 2 11 385 42670
ALDH4A1 Delta-1-pyrroline-5- carboxylate
dehydrogenase, mitochondrial 256 0 41 22 1 563 61719
ALDH5A1 Succinate-semialdehyde
dehydrogenase, mitochondrial 437 8 192 19 6 535 57215
ALDH6A1
Methylmalonate-Semialdehyde
dehydrogenase [acylating],
mitochondrial
131 0 13 17 14 535 5784
ALDH7A1 Alpha-aminoadipic semialdehyde
dehydrogenase 2268 95 563 29 5 510 55235
ALDH8A1 Aldehyde dehydrogenase family 8
member A1 2 0 0 2 6 487 53401
ALDH9A1 4-trimethylaminobutyral dehyde
dehydrogenase 1096 98 365 22 1 491 53374
investigated could be classiﬁed as either epithelial or mes-
enchymal based on their morphology and their expression
of vimentin and E-cadherin. ALDH protein expression was
examined in relation to cell line epithelial/mesenchymal
characteristics. ALDH1A3, ALDH1B1, and ALDH18A1
exhibited statistically signiﬁcant diﬀerences in their MS
counts in epithelial versus mesenchymal cell lines (Table 3,
Figure 2). Whereas the stem cell markers ALDH1A1 and
ALDH3A1, did not yield statistically signiﬁcant diﬀerences
between epithelial and mesenchymal cell lines, a very high
number of MS spectral counts were observed for ALDH1A1
inthetwomesenchymalcelllinesH522andH1703(Table 3).
The extent of peptide coverage for ALDH1A3, ALDH1B1,
and ALDH18A1 between epithelial and mesenchymal cell
lines appears to be related to the total number of MS
countsratherthantoepithelial/mesenchymalcharacteristics,
as shown in Figure 3 for ALDH1A3 in TCE.
3.4. Lung Cancer Sera Exhibit IgG-Based Reactivity to
ALDH1A1. H522 tumor cell line proteins were separated
by 2D PAGE and transferred onto Immobilon-P PVDF
membranes, and the membranes were used to screen
individual lung cancer and control sera for autoantibodies
directed against H522 proteins. Sera from 25 lung cancer
patients (9 adenocarcinomas, 6 small cell, and 10 squamous
lung cancers) and 25 age- and sex-matched healthy controls
were investigated. Two neighboring spots, both with similar
apparent molecular weight (approximately 55kDa) but
slightly diﬀerent isoelectric points (6.6 and 6.45, resp.), were
observedtoexhibitfrequentreactivityinlungcancerpatients6 International Journal of Proteomics
Table 2: Identiﬁed Aldehyde Dehydrogenases in cell line H522.
Gene symbol MS/MS counts (TCE) MS/MS counts (Med) MS/MS counts (Surf)
ALDH16A1 4 1 1
ALDH18A1 31 0 6
ALDH1A1 2053 1706 173
ALDH1A3 0 0 1
ALDH1B1 39 0 24
ALDH1L2 0 0 3
ALDH2 29 3 47
ALDH3A1 0 0 8
ALDH3A2 3 0 2
ALDH4A1 15 0 0
ALDH5A1 15 0 5
ALDH7A1 164 2 26
ALDH9A1 21 0 8
Table 3: Occurrence of ALDH1A1, ALDH3A1, ALDH1A3, ALDH1B1 and ALDH18A1 in cell lines with epithelial or mesenchymal features.
Cell Lines EMT ALDH1A1 ALDH3A1 ALDH1A3 ALDH1B1 ALDH18A1
TCE Med Surf TCE Med Surf TCE Med Surf TCE Med Surf TCE Med Surf
H1437 Epithelial 82 2 0 0 6 2 0 0 0 33 0 9 18 0 16
H1650 Epithelial 0 0 0 0 0 0 3 0 0 11 0 5 4 0 0
H3255 Epithelial 0 0 0 0 0 0 0 0 0 2 0 0 8 0 5
HCC4019 Epithelial 0 0 0 0 0 0 93 0 19 29 0 6 0 0 0
DFC1032 Epithelial 0 0 0 0 0 3 247 112 77 17 0 7 0 0 16
HCC827 Epithelial 0 0 0 0 0 2 65 0 0 81 1 14 14 0 5
H1573 Epithelial 0 0 0 129 0 0 0 0 0 6 0 0 1 0 13
HCC4011 Epithelial 0 0 0 0 0 0 91 10 5 40 0 12 12 0 13
H1819 Epithelial 0 0 0 0 0 0 8 0 0 6 0 3 6 0 9
H1395 Epithelial 8 0 0 4 3 8 0 0 0 49 0 12 9 0 4
H969 Epithelial 134 108 33 7 1 0 0 0 0 11 0 6 62 0 20
H820 Epithelial 0 0 0 0 0 4 67 2 14 171 14 66 27 3 17
H2291 Epithelial 0 0 0 0 0 0 3 0 2 7 0 19 8 2 22
HCC4017 Epithelial 0 0 0 0 0 0 234 93 5 35 1 3 9 0 8
HCC2935 Epithelial 5 0 0 0 6 0 205 8 73 16 0 3 2 0 11
H1299 Mesenchymal 0 0 0 4 0 0 0 0 2 3 0 5 0 0 3
H23 Mesenchymal 0 0 0 0 0 0 0 0 0 0 0 13 0 0 0
H 8 3 8M e s e n c h y m a l 000001002002000
H2030 Mesenchymal 0 0 0 0 0 0 0 0 0 0 0 0 0 0 5
H 6 5 0M e s e n c h y m a l 000000000604000
DFC1024 Mesenchymal 0 0 0 0 0 0 17 0 42 20 0 6 2 0 5
H1355 Mesenchymal 34 2 0 0 0 13 0 0 1 11 0 7 17 0 11
H2405 Mesenchymal 2 0 0 0 0 41 0 0 0 2 0 9 5 0 4
H522 Mesenchymal 2053 1706 173 0 0 8 0 0 1 39 0 24 31 0 6
H1703 Mesenchymal 1665 354 78 0 0 7 0 0 18 20 1 30 10 0 15
(Figure 4). The data for the more acidic spot was highly
correlated to the more basic spot values, giving a Spearman’s
rank correlation of 0.62 with a P value of 2.3 × 10
−6.T h e
more basic spot was excised from gels on two occasions
and digested with trypsin, with the resulting tryptic digests
subjectedtomassspectrometricanalysis.Weobtained46and
45spectramatchingthealdehydedehydrogenase1A1protein
(NP 000680, gene symbol ALDH1A1) on the two runs.
Thesematchesamountedto26and22distinctpeptides,with
MASCOT search engine scores of 1503 and 1464, respec-
tively. The more acidic spot was also identiﬁed as ALDH1A1,
with 21 matching peptides and MASCOT score of 1329.
Spot integrated intensities on the ﬁlms were measured
and analyzed by one-sided Rank-Sum tests. We obtainedInternational Journal of Proteomics 7
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Figure 4: Occurrence of autoantibodies to ALDH1A1 in lung-
cancer. A rectangle marks the location of ALDH1A1 in a silver-
stained 2D gel of H522 lysate, also shown in a close-up below (A).
The acidic and basic ALDH1A1 reactive spots in Western blots
hybridized with subject sera (B and C) are indicated with arrows.
estimated P values of 0.0018 (basic) and 0.0026 (acidic)
from 10000 permuted data sets, indicating greater reactivity
in lung cancer patients compared to healthy controls.
Two receiver operating characteristic (ROC) curves were
constructed, each using the data for a single protein spot
(either the more basic or more acidic spot). For the more
basic spot, an AUC of 0.69 was obtained. An AUC of 0.68
was obtained for the more acidic spot.
4. Discussion
Comprehensive proteomic proﬁling delineated the range of
expression and localization of ALDHs in total cell lysates,
the cell surface, and their release into the media of cultured
lung adenocarcinoma cell lines. A striking ﬁnding is the
extent to which ALDHs localize to the cell surface and/or
are released into the media. The evidence obtained based on
the peptides identiﬁed for various ALDHs does not suggest
the occurrence of distinct forms of ALDHs in diﬀerent
compartments,thusthemechanismsinvolvedandtheroleof
ALDHs localized to the cell surface or release into the media
largely remain to be determined.
WeobservedadistinctpatternofexpressionofALDHsin
cell lines exhibiting epithelial versus mesenchymal features.
In other studies, ALDH expression was found to mark
pancreatic cancer cells that have stem cell and mesenchymal
features[22].ALDHexpressionwasanalyzedbyimmunohis-
tochemistry in 269 primary surgical specimens of pancreatic
adenocarcinoma and examined for association with clinical
outcomes and in paired primary tumors and metastatic
lesions from eight pancreatic cancer patients who had par-
ticipated in a rapid autopsy program. The clonogenic growth
potential of ALDH-positive pancreatic adenocarcinoma cells
was assessed in vitro by a colony formation assay and by
tumor growth in immunodeﬁcient mice. ALDH-positive
tumor cells were detected in 90 of the 269 primary surgical
specimens, and their presence was associated with worse
survival. Six of the eight patients with matched primary
and metastatic tumor samples had ALDH-negative primary
tumors, and in four of these six patients, the matched
metastatic lesions contained ALDH-positive cells which
expressed genes consistent with a mesenchymal state [22].
The extent to which mesenchymal features correlate
with a stem cell phenotype reﬂected in a common ALDH
expression pattern remains to be determined. In our studies,
ALDH1A1 and ALDH3A1, which have been associated with
stem cell features, exhibited distinct expression patterns
among the cell lines analyzed. ALDH3A1 did not yield a sig-
niﬁcant association with a mesenchymal phenotype whereas
ALDH1A1 exhibited strikingly high expression based on MS
counts in two cells lines with a mesenchymal phenotype.
Moreover, ALDH1A3, ALDH1B1, and ALDH18A1 exhibited
a statistically signiﬁcant diﬀerence in their protein expres-
sion between cell lines with epithelial and mesenchymal
features.
We utilized lysates from H522, a lung adenocarcinoma
cell line that expresses high levels of ALDH1A1 to charac-
terize the humoral immune response in lung cancer. We
obtained evidence for autoreactivity against two forms of
A L D H 1 Ai ns e r af r o ms u b j e c t sw i t hl u n gc a n c e rr e l a t i v et o
healthy controls. The reactivity observed was not limited to
lung adenocarcinoma, as sera from subjects with squamous
cell lung cancer and small cell lung cancer exhibited similar
reactivity. An immune response to ALDH1A1 has been
reported in other studies. ALDH1A1 was identiﬁed as a
novel CD8+ T-cell-deﬁned tumor antigen in squamous cell
carcinoma of the head and neck [23]. Mass spectral analysis
of peptides in tumor-derived lysates was used to determine
thattheCTLlinerecognizedtheHLA-A2binding ALDH1A1
(88–96)peptide.ALDH1A1(88–96)peptide-speciﬁcCD8(+)
T cells recognized only HLA-A2(+) cell lines which over
expressed ALDH1A1 and cells transfected with ALDH1A1
cDNA. In another study, sera from three of ﬁve patients with
lung adenocarcinoma and none of ten controls with lung
tuberculosis were found to exhibit IgG-based seroreactivity
against aldehyde dehydrogenase identiﬁed in A549 lung
adenocarcinoma cell line lysate using an approach similar to
the approach for IgG reactivity against ALDH1A1 utilized in
this study [24].
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